News | June 03, 2022
GSK to form consumer healthcare business ‘Haleon’
The proposed demerger is the most significant corporate change for GSK in the last 20 years
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
Subscribe To Our Newsletter & Stay Updated
